Brii Biosciences Ltd
7SS
Company Profile
Business description
Brii Biosciences Ltd is a biotechnology company based in China and the United States. It is committed to developing advancing therapies for infectious diseases, such as HBV, HIV, MDR/XDR gram-negative infections, and other illnesses, such as CNS diseases, which have public health burdens in China and around the world. The company's pipeline of products includes more than 10 product candidates that focus on infectious diseases and mental illnesses.
Contact
No. 1 North Yongtaizhuang Road
3rd Floor, Building 7, Zhongguancun Dongsheng
International Science Park
Haidian District
Beijing100192
CHNSector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
98
Stocks News & Analysis
stocks
Ask the analyst: Are Qantas shares a value trap?
Qantas’ pandemic woes seem a distant memory. But could the party end sooner than investors think?
stocks
Palantir earnings: Blockbuster growth amid high expectations
We raise our fair value estimate off the back of earnings.
stocks
ResMed earnings: Solid showing from ASX healthcare winner
Strong demand growth and improved profit margins lead to a strong result from the sleep apnea device firm.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,111.10 | 82.30 | 0.91% |
| CAC 40 | 7,634.21 | 13.17 | 0.17% |
| DAX 40 | 23,895.96 | 49.89 | 0.21% |
| Dow JONES (US) | 44,111.74 | 61.90 | -0.14% |
| FTSE 100 | 9,161.05 | 18.32 | 0.20% |
| HKSE | 24,910.63 | 8.10 | 0.03% |
| NASDAQ | 20,916.55 | 137.03 | -0.65% |
| Nikkei 225 | 40,794.86 | 245.32 | 0.60% |
| NZX 50 Index | 12,880.16 | 3.12 | 0.02% |
| S&P 500 | 6,299.19 | 30.75 | -0.49% |
| S&P/ASX 200 | 8,843.70 | 73.30 | 0.84% |
| SSE Composite Index | 3,633.99 | 16.40 | 0.45% |